Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction
Søren Lund Kristensen, David Preiss, Pardeep S. Jhund, et al.
Circulation Heart Failure (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 337

Showing 1-25 of 337 citing articles:

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino, Peter J Grant, Victor Aboyans, et al.
European Heart Journal (2019) Vol. 41, Iss. 2, pp. 255-323
Open Access | Times Cited: 4088
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 632
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Mark C. Petrie, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2018) Vol. 20, Iss. 5, pp. 853-872
Open Access | Times Cited: 587
Heart Failure in Type 2 Diabetes Mellitus
Helena Kenny, E. Dale Abel
Circulation Research (2019) Vol. 124, Iss. 1, pp. 121-141
Open Access | Times Cited: 535
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
Shannon M. Dunlay, Michael M. Givertz, David Aguilar, et al.
Circulation (2019) Vol. 140, Iss. 7
Open Access | Times Cited: 486
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 5, pp. 665-675
Open Access | Times Cited: 369
The global epidemics of diabetes in the 21st century: Current situation and perspectives
Eberhard Standl, Kamlesh Khunti, Tina Birgitte Hansen, et al.
European Journal of Preventive Cardiology (2019) Vol. 26, Iss. 2_suppl, pp. 7-14
Open Access | Times Cited: 364
2019 EACTS Expert Consensus on long-term mechanical circulatory support
Evgenij Potapov, Christiaan F J Antonides, María G. Crespo‐Leiro, et al.
European Journal of Cardio-Thoracic Surgery (2019) Vol. 56, Iss. 2, pp. 230-270
Open Access | Times Cited: 319
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Jelena P. Seferović, Brian Claggett, Sara B. Seidelmann, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 5, Iss. 5, pp. 333-340
Open Access | Times Cited: 317
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 337-349
Open Access | Times Cited: 278
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1670-1690
Open Access | Times Cited: 221
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
Milton Packer
Circulation (2017) Vol. 136, Iss. 16, pp. 1548-1559
Closed Access | Times Cited: 199
Diabetic Cardiomyopathy
Stefania Paolillo, Fabio Marsico, Maria Prastaro, et al.
Heart Failure Clinics (2019) Vol. 15, Iss. 3, pp. 341-347
Closed Access | Times Cited: 192
The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 11, pp. 1402-1411
Open Access | Times Cited: 188
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction
Koen W. Streng, Jan F. Nauta, Hans L. Hillege, et al.
International Journal of Cardiology (2018) Vol. 271, pp. 132-139
Open Access | Times Cited: 171
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Petar Seferović, Andrew J.S. Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 196-213
Open Access | Times Cited: 155
Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation
Gianluigi Savarese, Takuya Kishi, Orly Vardeny, et al.
JACC Heart Failure (2022) Vol. 11, Iss. 1, pp. 1-14
Open Access | Times Cited: 152
Comparative study on the predictive value of TG/HDL-C, TyG and TyG-BMI indices for 5-year mortality in critically ill patients with chronic heart failure: a retrospective study
Zijing Zhou, Qiang Liu, Min Zheng, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 26
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
Milton Packer, Brian Claggett, Martin Lefkowitz, et al.
The Lancet Diabetes & Endocrinology (2018) Vol. 6, Iss. 7, pp. 547-554
Closed Access | Times Cited: 146
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Damilola D. Adingupu, Sven Göpel, Julia Grönros, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 141
Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology
Eswar Kandaswamy, Li Zuo
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 424-424
Open Access | Times Cited: 134
Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy
Isabella Evangelista, Ranuccio Nuti, Tommaso Picchioni, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3264-3264
Open Access | Times Cited: 125
Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America
Shannon M. Dunlay, Michael M. Givertz, David Aguilar, et al.
Journal of Cardiac Failure (2019) Vol. 25, Iss. 8, pp. 584-619
Closed Access | Times Cited: 120
Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry
Marco Dauriz, Giovanni Targher, Cécile Laroche, et al.
Diabetes Care (2017) Vol. 40, Iss. 5, pp. 671-678
Open Access | Times Cited: 119
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
Franco Cosmi, Li Shen, Michela Magnoli, et al.
European Journal of Heart Failure (2018) Vol. 20, Iss. 5, pp. 888-895
Open Access | Times Cited: 105
Page 1 - Next Page

Scroll to top